ESMO 2026: Six Advances Reshaping Oncology and Clinical Development
By Vlad Bogin, MD, FACP
CEO, Cromos Pharma
Oncology innovation is entering a new phase. Developing a therapy against a previously difficult target is no longer enough. Increasingly, new treatments must outperform established options, demonstrate meaningful clinical benefits, and deliver those results in carefully defined patient populations.
At ESMO 2026, six developments stood out to me. They ranged from individualized cancer vaccines and entirely new therapeutic mechanisms to survival gains with antibody-drug conjugates, bispecific antibodies, and targeted therapies.
Together, they point to a fundamental shift: the science is becoming more sophisticated, and the demands on clinical development are rising just as quickly.
Here is what caught my attention, and why it matters beyond the individual trial results.
Personalized Cancer Vaccines Show Phase III Success in Melanoma
For years, personalized cancer vaccines represented an exciting but extraordinarily complex scientific proposition. ESMO 2026 offered important evidence that this approach can succeed in a large, randomized Phase III trial.
In the INTerpath-001 study, Merck and Moderna evaluated intismeran autogene, an individualized mRNA-based neoantigen therapy, combined with pembrolizumab in 1,137 patients with resected high-risk melanoma.
The combination reduced the relative risk of recurrence or death by 42% compared with pembrolizumab alone (HR 0.58). At two years, recurrence-free survival was 82.2% versus 70.0%, an absolute difference of 12.2 percentage points.
Equally important, individualized treatment was successfully manufactured for more than 99% of patients assigned to the combination arm.
That is a remarkable operational achievement. Unlike conventional medicines produced in standardized batches, these therapies must be designed and manufactured using the molecular characteristics of each patient’s tumor.
Overall survival data remain immature, and the long-term clinical impact is still being established. Nevertheless, the findings represent an important milestone for individualized cancer immunotherapy.
What this means for drug development: Personalized medicine is moving beyond biomarker-based drug selection toward therapies manufactured for individual patients. This introduces entirely new clinical development challenges, including tumor sequencing, manufacturing turnaround times, treatment scheduling, and coordination between sponsors, laboratories, sites, and patients. Successful execution will increasingly depend on integrating these processes into trial design from the outset.
A New Way to Attack Prostate Cancer: RIPTACs Show Encouraging Early Results
Not every important oncology advance comes from improving an existing therapeutic class. Some introduce an entirely different way of targeting cancer.
Johnson & Johnson presented early clinical results for JNJ-6143, an investigational oral RIPTAC therapy, in heavily pretreated metastatic castration-resistant prostate cancer.
Among 16 patients with measurable disease, 12 achieved confirmed objective responses, representing a 75% response rate. At the 50 mg dose, 77% of 38 evaluable patients experienced a prostate-specific antigen reduction of at least 50%.
RIPTACs are designed to bring proteins into proximity in a way that disrupts functions essential to cancer-cell survival. The approach potentially opens a new therapeutic avenue beyond conventional receptor inhibition and cytotoxic therapies.
The results are encouraging, but this remains Phase I evidence. The patient numbers are small, follow-up is limited, and response durability and comparative clinical benefit remain uncertain.
What this means for drug development: Novel mechanisms can produce striking early efficacy signals, but the transition from Phase I excitement to registrational success remains challenging. Dose optimization, biomarker development, toxicity characterization, and evidence of durable benefit will be critical. A high response rate is a reason to investigate further, not a substitute for demonstrating long-term clinical value.
Beyond Conventional Immunotherapy: New Treatment Approaches Extend Survival
Some of the most consequential results at ESMO 2026 came from therapies that combine highly selective targeting with powerful antitumor activity.
In extensive-stage small cell lung cancer, the Phase III DeLLphi-305 trial evaluated the DLL3-directed T-cell engager tarlatamab in combination with durvalumab maintenance therapy.
Median overall survival reached 21.1 months versus 12.7 months with durvalumab alone, representing a reported 58% reduction in the hazard of death.
For a disease historically associated with limited treatment options and poor outcomes, this is a clinically important result. However, the benefits must be weighed against the safety challenges of T-cell-engaging therapies, including cytokine release syndrome.
Antibody-drug conjugates (ADCs) also delivered noteworthy results.
In the Phase III TroFuse-005 study, sacituzumab tirumotecan improved median overall survival to 19.0 months compared with 12.1 months in previously treated endometrial cancer, with a reported 32% reduction in the hazard of death.
Meanwhile, the Phase III CLARITY-Gastric01 study of the CLDN18.2-directed ADC sonesitatug vedotin demonstrated an overall survival benefit in advanced gastric cancer, despite not meeting its progression-free survival endpoint.
That last finding deserves particular attention. A treatment can show an important survival advantage while failing to demonstrate statistical significance on another prespecified endpoint. Such results highlight the complexities of trial design, statistical testing, and regulatory interpretation.
What this means for drug development: The growing success of bispecific immunotherapies and ADCs is raising expectations for clinical benefit, but also introducing increasingly complex safety and operational requirements. Endpoint strategy, adverse-event management, specialized site capabilities, and long-term follow-up are no longer secondary considerations. They can determine whether a promising therapy succeeds in clinical development.
The Next Test for Precision Oncology: Beating Established Targeted Therapies
Precision oncology has traditionally focused on identifying actionable molecular alterations and developing drugs against them.
Now, the competitive landscape is changing.
In the Phase III Krascendo 1 trial, Roche’s KRAS G12C inhibitor divarasib was compared directly with the approved inhibitors sotorasib and adagrasib in previously treated non-small cell lung cancer.
Median progression-free survival was 9.8 months versus 5.7 months, while median overall survival was 17.7 versus 12.0 months. The reported hazard ratio for overall survival corresponded to a 44% reduction in the hazard of death.
This is an important development. It demonstrates that even within an established targeted-therapy class, meaningful improvements in outcomes remain possible.
The Phase III SAFFRON trial provided another example of precision oncology evolving beyond initial targeted treatment. The combination of osimertinib and savolitinib demonstrated a survival benefit over chemotherapy in patients with EGFR-mutated, MET-altered non-small cell lung cancer following progression on osimertinib.
Together, these studies illustrate a maturing field in which understanding resistance mechanisms and demonstrating superiority over existing therapies are becoming central development priorities.
What this means for drug development: Identifying an actionable mutation is increasingly only the starting point. Sponsors must establish where their therapy fits within an evolving treatment sequence and demonstrate meaningful differentiation. This places greater demands on molecular screening, access to comprehensive genomic testing, biomarker-defined recruitment, and careful comparator selection. As eligible populations become narrower, site feasibility and patient identification become even more consequential.
Treating Cancer Earlier: New Combinations Improve Outcomes
Another important trend at ESMO 2026 was the movement of innovative therapies into earlier disease settings, where the potential for long-term benefit may be greater.
The Phase III VOLGA trial evaluated perioperative durvalumab combined with neoadjuvant enfortumab vedotin in cisplatin-ineligible patients with muscle-invasive bladder cancer.
Pathological complete response was approximately 45% versus 10% in the control group, accompanied by improvements in event-free and overall survival.
However, the efficacy gains came with additional toxicity. Grade 3 or higher adverse events were reported in approximately 71% versus 50% of patients in the relevant treatment and control groups.
Similarly, the Phase III DASL-HiCaP trial demonstrated that adding darolutamide to androgen deprivation therapy and radiotherapy improved four-year metastasis-free survival to 95%, compared with 88% in the control group, among patients with high-risk localized prostate cancer.
These findings reinforce the potential value of intensifying treatment earlier in the disease course, before progression or metastatic spread.
But they also raise a critical question: how do we balance the possibility of better long-term outcomes against additional toxicity in patients who may otherwise remain disease-free for years?
What this means for drug development: Earlier-stage oncology trials demand particularly careful benefit-risk assessment. Pathological response and intermediate endpoints can provide important early evidence, but long-term survival, functional outcomes, toxicity, and quality of life remain essential. Patient selection becomes especially important when more intensive treatment is being considered for potentially curable disease.
China’s Oncology Innovation Is Becoming a Global Force
One of the broader developments evident at ESMO 2026 was the growing influence of China-originated therapies on the global oncology pipeline.
The Phase III HARMONi-GI1 trial evaluated Akeso’s PD-1/VEGF bispecific antibody ivonescimab plus chemotherapy against durvalumab plus chemotherapy in first-line biliary tract cancer.
Median overall survival reached 14.9 months versus 12.1 months, with a reported 25% reduction in the hazard of death.
Other examples of China-originated innovation include sacituzumab tirumotecan, developed by Kelun-Biotech and partnered with Merck.
These are not simply regional development stories. They reflect the emergence of increasingly sophisticated therapeutic platforms capable of generating clinically competitive results.
However, success in one geographic population does not automatically translate into regulatory acceptance worldwide. Differences in patient characteristics, prior treatment patterns, standards of care, and regulatory expectations must be considered when designing global development programs.
What this means for drug development: China is becoming an increasingly important source of oncology innovation, but global development requires more than positive regional trial results. Sponsors need early regulatory alignment, globally relevant comparators, appropriate population representation, and a clear strategy for multinational evidence generation. International clinical development planning should begin well before pivotal studies are completed.
The Bigger Picture: Scientific Innovation Is Raising the Bar for Clinical Development
What struck me most about ESMO 2026 was not any single result. It was the convergence of several trends that are fundamentally changing how oncology drugs are developed.
Personalized cancer vaccines are bringing individualized manufacturing into clinical trials. Novel therapeutic mechanisms are expanding the range of potential cancer targets. ADCs and bispecific antibodies are delivering meaningful survival improvements while introducing new safety considerations. Precision oncology is moving toward direct competition between increasingly sophisticated therapies. And innovation is becoming more geographically diverse.
Each of these advances creates opportunities for patients. Each also makes clinical development more demanding.
For sponsors, the implications are clear. A promising mechanism of action is only the beginning. Successful development increasingly depends on identifying the right patients, selecting meaningful endpoints, choosing appropriate comparators, anticipating operational complexity, and generating evidence that will withstand both scientific and regulatory scrutiny.
At Cromos Pharma, these are challenges we encounter across oncology development programs. Through realistic feasibility assessments, specialized clinical site networks, thoughtful recruitment strategies, and multinational trial execution, we help sponsors navigate the growing complexity of bringing innovative therapies into clinical testing.
The next generation of oncology breakthroughs will require more than extraordinary science. It will require equally sophisticated clinical development.
And ultimately, that is what matters: translating scientific progress into meaningful improvements in patients’ lives.
Developing an innovative oncology therapy? Connect with Cromos Pharma at inquiry@cromospharma.com to discuss your clinical development strategy.
